Syndax Pharma Updates On Interim Phase 1 Data From SNDX-5613 Leukemia Trial

  • Syndax Pharmaceuticals Inc SNDXin its Q1 earnings, also announced new data from the ongoing Phase 1 dose-escalation portion of the Phase 1/2 AUGMENT-101 trial evaluating SNDX-5613 in patients with MLLr and NPM1c mutant relapsed/refractory (R/R) acute leukemias.
  • The new data showed that two prior responders have improved from a complete response with incomplete platelet recovery (CRp) to a complete response (CR) with no evidence of minimal residual disease (MRD)
  • With the addition of these two patients, a total of 7/31 patients (23%) have achieved CR/CRh.
  • Syndax announced positive data from the Phase 1 portion of the AUGMENT-101 trial last month.
  • As of the data cutoff date, the overall response rate (ORR) among evaluable patients was 48% (n=15), with 67% (n=10) of these responders achieving MRD- status and four moving to receive stem cell transplant.
  • The ORR in evaluable patients harboring an MLL-rearrangement (n=24), was 54% (n=13), and in evaluable patients harboring an NPM1c mutation (n=7), was 29% (n=2).
  • Syndax remains on track to initiate the pivotal Phase 2 portion of the trial this quarter.
  • Q1 Earnings: Syndax clocked a net loss of $27.7 million or ($0.54) per share, higher than $19.1 million or $0.56 per share a year ago.
  • Increased clinical trial activities and CMC activities resulted in higher R&D expenses of $21.9 million, up from $9.6 million in Q1 2020.
  • The company ended the quarter with cash, cash equivalents, and short-term investments of $271.3 million.
  • Guidance: For Q2 2021, R&D expenses are expected to be $30 million - $35 million, and total operating costs are seen at $35 million - $40 million.
  • For FY21, Syndax forecasts R&D expenses of $90 million - $100 million and total operating expenses of $110 million - $120 million.
  • Price Action: SNDX shares closed at $16.04 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareSmall CapFDAGeneralBriefsleukemiaPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!